YUNNAN BAIYAO(SZ:000538) Xin Lang Cai Jing·2026-01-08 05:23Core Viewpoint - The controversy surrounding Yunnan Baiyao toothpaste centers on the inclusion of tranexamic acid, a prescription drug commonly used for its hemostatic properties, raising questions about the product's marketing claims and safety [2][4][7]. Group 1: Product Composition and Claims - Yunnan Baiyao toothpaste claims to have a market share ranking second nationally and first among domestic brands, with its hemostatic properties being a key selling point [2][15]. - The toothpaste contains tranexamic acid, which is a prescription medication used in clinical settings for excessive bleeding and has specific side effects [4][7]. - The company asserts that tranexamic acid is a common ingredient in many functional toothpastes and that its formulation is safe [7][8]. Group 2: Regulatory and Consumer Concerns - Tranexamic acid is not listed among prohibited ingredients in the regulations for toothpaste, allowing its use in cosmetic products [5][8]. - There are concerns regarding the dosage of tranexamic acid in the toothpaste and its potential effects on human health, which remain unclear [8][10]. - The company has faced previous legal challenges regarding the efficacy claims of its toothpaste, indicating a history of consumer skepticism [10][14]. Group 3: Financial Performance and Market Position - Yunnan Baiyao's toothpaste significantly contributes to the company's profits, with the health products segment accounting for nearly 59% of the net profit in the first half of 2018 [17]. - The toothpaste has rapidly gained market share, achieving an 18.1% share by May 2018, reflecting a year-on-year growth of 11% [15][17].